_256_384.jpg)
News | July 26, 2025
Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Revenue increased 11.4 per cent to Rs. 8,545 crore
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Subscribe To Our Newsletter & Stay Updated
